Skip to main content
OpenTrials
Completed

NCT Number: NCT02515812

Comparative Study of Cardiac Adrenergic Function Explored by I-123-MIBG and CZT Camera (D-SPECT) Versus Anger Camera in Patients With Heart Failure

Cardiological examination constitute one of the major directions in nuclear medicine for detection of myocardial ischemia in patients suspected of coronary disease. In Caen, they constitute 20% of the activity of nuclear medicine. Systolic heart failure (HF) ischemic or nonischemic origin represents a new area of activity of the nuclear cardiology. This is HF stratification study based on cardiac adrenergic function after injection of a tracer: I-123-MIBG. The team Caen nuclear cardiology is one of two teams recognized internationally in the field of evaluating the cardiac sympathetic innervation in cardiomyopathies. Numerous publications from 1992 to the present day have reported encouraging results for the daily use of this tracer in the evaluation of patients with LV dysfunction IC. Recently, interest in using the MIBG has been shown as a prognostic marker of HF in a prospective study of 961 patients. Typically, the camera used was an Anger camera with collimating Nai standard called parallel holes.

The main objective is to validate the measurements of cardiac adrenergic function evaluated by cardiopulmonary mediastinal reports and sympathetic innervation scores VG after injection of I-123-MIBG in 80 patients with heart failure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Médecine Nucléaire -CHU de Caen

Caen, 14000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age above 18 years (except major patients under guardianship)
  • patient who signed the consent form
  • written and spoken French
  • Beneficiaries of the social security system
  • Stable heart failure with LV dysfunction (<45%) of ischemic or nonischemic origin

Exclusion criteria

  • Patients with a recent history (<21 days) acute coronary failure (myocardial infarction, unstable angina)
  • Patients with severe extra-cardiac disease may interfere with treatment decisions (cancer, severe hepatic or renal impairment)
  • Major patients under guardianship
  • Pregnant or lactating women
  • Women in age and condition of childbearing
  • Patients unable to understand the purpose of the study

Treatment and study plan

I-123-MIBG

Drug

CZT Camera (D-SPECT)

Device

Anger Camera

Device

Primary outcomes

  1. SRSI (summed rest score innervation)

    Time frame: 4 hours after I-123-MIBG perfusion

    with CZT camera and Anger camera

  2. SRS (summed rest score)

    Time frame: 4 hours after I-123-MIBG perfusion

    with CZT camera and Anger camera

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Registry information

Acronym: ADRECARD

Important dates

Study start
2012
Primary completion
2014
First posted
Aug 5, 2015
Registry last updated
Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.